

Putting data to work: Accelerating the recovery from the pandemic

Andrew Huxter Vice President, Northern Europe and Growth Markets

MedTech Forum 2022e^{Me}Barcelona 4 May, 14:15 to 15:05


ResMed: Who we are

- World-leading digital health compary with over 16 million 100% cloud-connectable devices
- Innovative designer and manufacturer of award-winning devices and cloud-based software solutions which diagnose, treat, and manage sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions
- Designed to improve patient outcomes and quality of life, reduce impact of chronic disease, as well as lower healthcare costs and improve efficiencies for healthcare providers:
 - 2022 The Meditech Forum. t - Tools that allow fewer people to manage more patients
 - Empower patients to track own health outcomes





ResMed is a Global leader in digital health



© 2022 ResMed | Corporate & Investor Presentation – updated 27JAN22

>16 million

100% cloud connectable devices worldwide


2+ million diagnostic tests processed in the cloud

million patients have signed up for myAir[™]



With proven solutions, turning data into actionable information

Pioneering innovation and providing clinical evidence that support better patient outcomes and improved business efficiencies for customers



et al., AJRCCM 2017

et al. Sleep Breath 2016

sed on monthly patient setups and

- © 2022 ResMed | Corporate & Investor Presentation updated 27JAN22



Leveraging our scale can enable a shift to proactive intervention

With more than 10.5 billion nights of therapy usage data we have a unique ability to create actionable onsights: s reserved - Reproduction

For Patients

Now

Coaching and usage help in context through myAir app


For Providers

 Patient management by exception, streamlined workflows, lower costs, higher adherence, and increased revenue

For Payors

 Increased patient adherence and improved ROI on therapy

Benefitting all stakeholders with better outcomes and lower costs





Which is critical in addressing the impact of Chronic disease, as the largest driver of healthcare spending in developed economies

- **Sleep apnea Leading indicator**, and a contributing of Reproduction in Mole of I are 'actor, to many chronic illnesses 're than 80% undiagnosed 'nstrated positive ship '
- relationship between CPAP usage and lower healthcare costs ో

2022 The Med Tec

COPD

- Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil, and E. Europe >100M²
- Acute treatment costs to healthcare systems are large
 - Europe: €48B per year⁴
 - U.S.: ~\$50B per year⁵
- More than 3M people worldwide die each year due to COPD¹

Total addressable patients

380M COPD patients^{2,3}

Well-positioned to expand proactive treatment of chronic diseases

¹World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16² https://www.ncbi.nlm.nih.gov/pubmed/26755942³ Company & mates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" Respiratory and Critical Care ⁴ European Respiratory Society, European Lung White Book http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease (OPD Fact sheet No315, 2015 accessed 20Jul16

6 © 2022 ResMed | Corporate & Investor Presentation – updated 27JAN22

936M sleep apnea patients

Asthma

- Significant opportunity to improve adherence and improve patient-physician interaction
 - Leveraging Propeller for increased data related to symptom occurrence and acute triggers "molt
 - Opportunity to partner with patients, providers, pharmaceutical companies, and gayors to drive improved quality of life

330M asthma patients⁶



What is required is an enabling framework to unlock the full potential of digital health

Three key enablers that will support the adoption of digital health across the EU:

- 1. Facilitate access to health data for research and innovation
- 2. Establish an internationally-aligned, harmonized and clear regulatory framework enabling data and Al-driven models of care and interoperability of DHTs across healthcare systems
- 3. Adopt Digital Health reimbursement models in EU Member States

The newly proposed EHDS is providing the starting points for addressing these challenges, but we need to ensure it is able to address them fully.

